Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton Buys 200,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton bought 200,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $0.56 per share, with a total value of $112,000.00. Following the purchase, the chief financial officer now directly owns 200,000 shares of the company’s stock, valued at approximately $112,000. This trade represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Lyell Immunopharma Stock Performance

LYEL stock opened at $0.48 on Wednesday. Lyell Immunopharma, Inc. has a one year low of $0.48 and a one year high of $3.15. The stock has a market capitalization of $142.80 million, a PE ratio of -0.61 and a beta of -0.41. The company has a fifty day moving average of $0.62 and a 200-day moving average of $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million during the quarter. Equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Centiva Capital LP acquired a new stake in Lyell Immunopharma in the third quarter valued at $31,000. Graham Capital Management L.P. purchased a new stake in Lyell Immunopharma during the fourth quarter worth $33,000. RPO LLC acquired a new stake in Lyell Immunopharma in the fourth quarter valued at $42,000. Intech Investment Management LLC purchased a new position in shares of Lyell Immunopharma in the third quarter valued at $52,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Lyell Immunopharma during the 3rd quarter worth $52,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.